Topic: Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumor
Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Trial has been completed -
Only 4 (4%) patients on the trial though had ICC.
CONCLUSIONS AND RELEVANCE:
We demonstrated that the treatment strategy of individualized adaptive therapy based on a direct biomarker of liver function can be used to achieve both high rates of local control and a high degree of safety without sacrificing either. Individualized adaptive radiotherapy may represent a new treatment paradigm in which dose is based on individual, rather than population-based, tolerance to treatment.